Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20).

Literature DB >> 16723592

Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20).

Xing-Quan Zhang¹, Meredith Sorensen, Michael Fung, Robert T Schooley.

Abstract

Recently, antiretroviral agents directed at several steps involved in viral entry have been shown to reduce viral replication in vitro and in vivo. We have demonstrated a high level of in vitro synergistic antiretroviral activity for two entry inhibitors that are directed at sequential steps in the entry process.

Entities: Chemical Gene

Mesh：

Substances：

Year: 2006 PMID： 16723592 PMCID： PMC1479151 DOI： 10.1128/AAC.00761-05

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

13 in total

1. A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties.

Authors: K A Reimann; W Lin; S Bixler; B Browning; B N Ehrenfels; J Lucci; K Miatkowski; D Olson; T H Parish; M D Rosa; F B Oleson; Y M Hsu; E A Padlan; N L Letvin; L C Burkly
Journal: AIDS Res Hum Retroviruses Date: 1997-07-20 Impact factor: 2.205

2. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion.

Authors: L C Burkly; D Olson; R Shapiro; G Winkler; J J Rosa; D W Thomas; C Williams; P Chisholm
Journal: J Immunol Date: 1992-09-01 Impact factor: 5.422

3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors: F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245

4. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro.

Authors: Cécile L Tremblay; Françoise Giguel; Christopher Kollmann; Yongbiao Guan; Ting-Chao Chou; Bahige M Baroudy; Martin S Hirsch
Journal: Antimicrob Agents Chemother Date: 2002-05 Impact factor: 5.191

5. Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates.

Authors: Louis Boon; Betty Holland; Wayne Gordon; Patrick Liu; Fred Shiau; William Shanahan; Keith A Reimann; Michael Fung
Journal: Toxicology Date: 2002-04-02 Impact factor: 4.221

6. A humanized, nondepleting anti-CD4 antibody that blocks virus entry inhibits virus replication in rhesus monkeys chronically infected with simian immunodeficiency virus.

Authors: Keith A Reimann; Rajinder Khunkhun; Wenyu Lin; Wayne Gordon; Michael Fung
Journal: AIDS Res Hum Retroviruses Date: 2002-07-20 Impact factor: 2.205

7. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.

Authors: Daniel R Kuritzkes; Jeffrey Jacobson; William G Powderly; Eliot Godofsky; Edwin DeJesus; Frances Haas; Keith A Reimann; Jeffrey L Larson; Patrice O Yarbough; Valentin Curt; William R Shanahan
Journal: J Infect Dis Date: 2004-01-08 Impact factor: 5.226

8. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells.

Authors: J P Moore; Q J Sattentau; P J Klasse; L C Burkly
Journal: J Virol Date: 1992-08 Impact factor: 5.103

9. In vivo administration to rhesus monkeys of a CD4-specific monoclonal antibody capable of blocking AIDS virus replication.

Authors: K A Reimann; L C Burkly; B Burrus; B C Waite; C I Lord; N L Letvin
Journal: AIDS Res Hum Retroviruses Date: 1993-03 Impact factor: 2.205

10. In vivo administration of CD4-specific monoclonal antibody: effect on provirus load in rhesus monkeys chronically infected with the simian immunodeficiency virus of macaques.

Authors: K A Reimann; R L Cate; Y Wu; L Palmer; D Olson; B C Waite; N L Letvin; L C Burkly
Journal: AIDS Res Hum Retroviruses Date: 1995-04 Impact factor: 2.205

22 in total

1. The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment.

Authors: W Jeffrey Fessel; Brooke Anderson; Stephen E Follansbee; Mark A Winters; Stanley T Lewis; Steven P Weinheimer; Christos J Petropoulos; Robert W Shafer
Journal: Antiviral Res Date: 2011-10-04 Impact factor: 5.970

2. Novel antiretroviral agents in HIV therapy.

Authors: Caitlin Reed; Eric S Daar
Journal: Curr Infect Dis Rep Date: 2006-11 Impact factor: 3.725

3. Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.

Authors: Jonathan Toma; Steven P Weinheimer; Eric Stawiski; Jeannette M Whitcomb; Stanley T Lewis; Christos J Petropoulos; Wei Huang
Journal: J Virol Date: 2011-02-02 Impact factor: 5.103

Review 4. Novel targets for antiretroviral therapy: clinical progress to date.

Authors: Birgitt Dau; Mark Holodniy
Journal: Drugs Date: 2009 Impact factor: 9.546

5. Octadecyloxyethyl benzyl tenofovir: A novel tenofovir diester provides sustained intracellular levels of tenofovir diphosphate.

Authors: James R Beadle; Kathy A Aldern; Xing-Quan Zhang; Nadejda Valiaeva; Karl Y Hostetler; Robert T Schooley
Journal: Antiviral Res Date: 2019-09-21 Impact factor: 5.970